sb 216763 has been researched along with Pneumonia in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Agostini, C; Biasutto, L; Brunetta, E; Cabrelle, A; Calabrese, F; Cinetto, F; Facco, M; Garbisa, S; Gattazzo, C; Gnoato, M; Gurrieri, C; Montini, B; Niero, R; Piazza, F; Semenzato, G | 1 |
Alapati, D; Chen, S; Hehre, D; Hummler, SC; Rong, M; Wu, S | 1 |
2 other study(ies) available for sb 216763 and Pneumonia
Article | Year |
---|---|
3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosis.
Topics: Animals; Bleomycin; Chemokine CCL2; Glycogen Synthase Kinase 3; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Macrophages; Maleimides; Mice; Mice, Inbred C57BL; Pneumonia; Pulmonary Alveoli; Respiratory Mucosa; Tumor Necrosis Factor-alpha | 2010 |
Targeting glycogen synthase kinase-3β to prevent hyperoxia-induced lung injury in neonatal rats.
Topics: Airway Remodeling; Animals; Animals, Newborn; Bronchopulmonary Dysplasia; Drug Evaluation, Preclinical; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Hyperoxia; Hypertension, Pulmonary; Indoles; Infant, Newborn; Injections, Intraperitoneal; Lung; Maleimides; Phosphorylation; Pneumonia; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Rats; Rats, Sprague-Dawley; Signal Transduction; Transcription Factor RelA | 2013 |